Therapy Areas: Central Nervous System
Tris Pharma expands ADHD Portfolio via acquisition of NextWave Pharmaceuticals
26 September 2018 -

Pharmaceutical company Tris Pharma Inc revealed on Tuesday the completion of the acquisition of NextWave Pharmaceuticals, a wholly owned subsidiary of Pfizer Inc, including two key Attention Deficit Hyperactivity Disorder (ADHD) treatments, for an undisclosed amount.

ADHD is one of the most common neurodevelopmental disorders characterized by an ongoing pattern of inattention and/or hyperactivity and impulsivity.

Following closing, the acquisition further expands Tris' portfolio of products for the treatment of patients with ADHD.

This acquisition includes Quillivant XR, the first and only marketed extended-release oral liquid methylphenidate as well as QuilliChew ER, the first and only extended-release methylphenidate chewable tablet, both of which are central nervous system (CNS) stimulants approved for the treatment of ADHD.

In addition, Quillivant XR and QuilliChew ER were co-developed by NextWave and Tris, utilizing Tris' novel, proprietary LiquiXR platform.

Login
Username:

Password: